|
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Mycelx Technologies Corp - Georgia, US-based clean water and air technology firm - Says it achieves profitability in 2025, materially outperforming market expectations, despite revenue coming in slightly below forecasts. The company expects 2025 revenue of about $11.7 million, up 140% from 2024 but below market expectations of $12.5 million. Mycelx expects earnings before interest, tax, depreciation and amortisation of around $680,000, compared with market expectations for a loss of $200,000, including a $160,000 gain from the sale of its Saudi Arabia operations. Pretax profit is expected to be around $360,000, versus expectations for a loss of $600,000. Mycelx ends the year with cash of $860,000 and expects to collect around $4 million in the first quarter of 2026. The company says it enters 2026 with a stronger earnings profile, increasing commercial momentum and remains optimistic about prospects for 2026 and beyond, while maintaining current-year guidance. ---------- Staffline Group PLC - Nottingham, England-based flexible staff recruitment in UK and Ireland - Reports higher earnings for 2025 in a trading update. Revenue rises 12% to £1.11 billion from £992.9 million, while pretax profit jumps 42% to £7.1 million from £5.0 million. It says the revenue increase was largely driven by a ‘significant new strategic partnership’ with a ‘leading logistics provider’ as well as ‘continued market share growth in the blue-collar sector’. ‘We are delighted to have delivered such a strong performance in financial 2025, underpinned by another successful Christmas peak trading period and significant new contract wins,’ says Chief Executive Officer Albert Ellis. ---------- Creo Medical Group PLC - Chepstow, Wales-based medical device company - Reports revenue growth in 2025 and says it is confident of meeting expectations in 2026. The company says revenue rises 50% to £6.0 million in 2025 from £4.0 million, as expected, driven by 58% growth in the second half to £3.8 million from £2.4 million a year earlier. Underlying operating costs fall 20% to £18.4 million, narrowing the underlying operating loss to £13.3 million from £22.3 million in 2024. Creo ends 2025 with cash of £12.4 million, up from £8.7 million a year earlier but down from £20.5 million at the end of June. The company says it sees continued clinical adoption and increased utilisation of its core products and is confident in delivering sequential growth in 2026. Chair Kevin Crofton says: ‘The second half of financial 2025 represents two more consecutive quarters of consistent delivery against management expectations.’ ---------- Flowtech Fluidpower PLC - Cheshire, England-based valves and hydraulic components maker - Reports higher full-year revenue and agrees a bolt-on acquisition, while launching a placing and retail offer to fund growth. The company expects financial 2025 revenue of £116.9 million, up 9.6% from £107.3 million year-on-year, and underlying Ebitda of around £7.7 million, in line with guidance, after stronger second-half trading. Flowtech says it enters 2026 with a stronger sales pipeline and order book, stable gross margins and lower overheads. Flowtech’s Benelux subsidiary agrees to acquire Netherlands-based pneumatics and automation specialist Q Plus for up to €5.9 million, a deal it says will double the size of its Benelux business and be earnings enhancing. To fund the acquisition and reduce debt, Flowtech proposes a £9 million placing of new shares at 53.0 pence each, alongside a retail offer of up to £1 million at the same price. Flowtech Fluidpower later confirms it conditionally raises £9 million through a placing of 17.0 million new shares at 53.0p each, with support from existing and new institutional investors. The placing shares represent about 21% of enlarged share capital, while directors subscribe £233,148. Flowtech also launches a retail offer to raise up to £1 million, with results expected on January 22. A general meeting is scheduled for February 6 to approve the fundraising, acquisition and capital reorganisation. ---------- JPMorgan Emerging Europe, Middle East & Africa Securities PLC - London-based trust - Says an appeal in relation to the $439.5 million claim brought by Russia’s VTB Bank is scheduled to be heard by the Court of Cassation on February 16. The trust says it will provide further updates as the Russian court cases progress. ---------- Thruvision Group PLC - Abingdon, England-based provider of walkthrough people-screening technology - Says it secures a South-East Asian mass transit contract via a regional integration partner, covering the deployment of 20 high-throughput people-screening systems for a major international rail link. The company expects the award to generate more than £1 million in revenue, with delivery due in the current quarter, and says an additional award for support services is anticipated in the next financial year. CEO Victoria Balchin says: ‘This award demonstrates the growing demand for our technology and, as the second major order in this region this financial year, reflects the increasing traction of our regional partner strategy in Asia, reinforcing confidence in its effectiveness across our established market sectors.’ ---------- Schroders Capital Global Innovation Trust PLC - London-based investment trust - Says its holding in the Salica Environmental Technology Fund has completed the sale of portfolio company Bluewater Bio Ltd to a European private equity-backed strategic buyer. The trust says expected distributions are in line with the valuation used in its third-quarter of 2025 net asset value and the transaction is not expected to result in a material change to its most recently published NAV. The disposal forms part of the ongoing wind-down of the trust, with the board intending to make a further return of capital to shareholders later in 2026. ---------- Sancus Lending Group Ltd - London-based alternative financial services provider - Says it issues £1.4 million of preference shares in subsidiary Sancus Loans Ltd to Somerston Fintech Ltd, under the Somerston junior funding commitment. The preference shares carry a non-cash, cumulative coupon of 15% and mature in November 2026. The issue is made under the junior funding commitment of up to £10 million announced in January 2025. Following the issue, Sancus says £1.6 million of the commitment remains undrawn. Sancus says the funding increases capital deployed in Sancus Loans for one of the group’s existing funding lines. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
